Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer
DOI: https://doi.org/10.2147/ijn.s450205
IF: 7.033
2024-04-18
International Journal of Nanomedicine
Abstract:Haohua Yuan, 1 Huan Gui, 1 Shuanghui Chen, 1 Lan Zhu, 1 Chenglv Wang, 1 Qianyu Jing, 2 Hang Lv, 1 Quan Wan, 2 Shuyi Wang, 1 Shengwen Zhou, 1 Xiaodong Ren, 1 Yingjie Nie, 1, 3 Linzhao Li 1 1 Medical College, Guizhou University, Guizhou Province, 550025, People's Republic of China; 2 School of Preclinical Medicine of Zunyi Medical University, Zunyi, Guizhou Province, 563000, People's Republic of China; 3 NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, 550002, People's Republic of China Correspondence: Yingjie Nie; Linzhao Li, Medical College of Guizhou University, Guiyang, Guizhou Province, 550025, People's Republic of China , Tel +86-085188274013 ; +86-085188274016 , Email ; Purpose: This study aimed to develop a novel and feasible modification strategy to improve the solubility and antitumor activity of resiquimod (R848) by utilizing the supramolecular effect of 2-hydroxypropyl-beta-cyclodextrin (2-HP-β-CD). Methods: R848-loaded PLGA nanoparticles modified with 2-HP-β-CD (CD@R848@NPs) were synthesized using an enhanced emulsification solvent-evaporation technique. The nanoparticles were then characterized in vitro by several methods, such as scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy, particle size analysis, and zeta potential analysis. Then, the nanoparticles were loaded with IR-780 dye and imaged using an in vivo imaging device to evaluate their biodistribution. Additionally, the antitumor efficacy and underlying mechanism of CD@R848@NPs in combination with an anti-TNFR2 antibody were investigated using an MC-38 colon adenocarcinoma model in vivo. Results: The average size of the CD@R848@NPs was 376 ± 30 nm, and the surface charge was 21 ± 1 mV. Through this design, the targeting ability of 2-HP-β-CD can be leveraged and R848 is delivered to tumor-supporting M2-like macrophages in an efficient and specific manner. Moreover, we used an anti-TNFR2 antibody to reduce the proportion of Tregs. Compared with plain PLGA nanoparticles or R848, CD@R848@NPs increased penetration in tumor tissues, dramatically reprogrammed M1-like macrophages, removed tumors and prolonged patient survival. Conclusion: The new nanocapsule system is a promising strategy for targeting tumor, reprogramming tumor -associated macrophages, and enhancement immunotherapy. Keywords: R848, 2-HP-β-CD, anti-TNFR2, TIME, immunotherapy Cancer remains the leading cause of global mortality, and its incidence is projected to increase by 47% by 2040. 1,2 Over the past decade, the development of immunotherapies has revolutionized cancer treatment and garnered attention from clinicians and cancer patients worldwide. 3–5 Cancer immunity is closely linked to the tumor immunosuppressive microenvironment (TIME), which is caused by tumor-associated macrophages (TAMs) and regulatory T cells (Tregs). 6 Notably, M2-like TAMs are prevalent among tumor-infiltrating immune cells, and their abundance often correlates with a poor prognosis. 7 Treatments for TAMs can be divided into the following principal strategies: 1) directly eliminating or depleting TAMs, 2) inhibiting the recruitment of TAMs, and 3) reprogramming tumor-promoting M2 macrophages within TAMs into antitumor M1 macrophages. The first approach may lead to unforeseen side effects, and inhibiting TAM recruitment could reduce therapeutic efficacy due to compensatory proliferation. 8 The third strategy can effectively reduce the number of M2 macrophages, increase the secretion of TNF-α, IL-6, and other cytokines, activate antitumor immune responses, reshape the immunosuppressive tumor microenvironment, and kill tumor cells. Numerous reports have demonstrated that tumors can be effectively treated by drug delivery systems that utilize a 'turn enemies into friends' approach, ushering in a new era of tumor treatment. 9–11 Resiquimod (R848) can polarize TAMs from the M2-like phenotype to the M1-like phenotype. 12–14 However, the pharmacokinetics of R848 are suboptimal, particularly when the drug is administered in the peritoneal cavity; due to its relatively small size, R848 is rapidly diffused and leads to subsequent systemic toxicity. 15–17 Conversely, the effectiveness of TLR7/8 agonists in cancer treatment may be improved by employing drug delivery strategies that enhance drug retention and targeted delivery while minimizing off-target toxicity. 17,18 Several nanomaterial-based immunomodulatory treat -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology